Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of YFQLXB-UC01 in moderate to severe acute respiratory distress syndrome
CTR20251847Phase 2Active
- Sponsor
- Qilu Cell Therapy
- Start
- May 2025
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of umbilical cord mesenchymal stem cells (Shandong Province Qilu Stem Cells Engineering) in acute respiratory distress syndrome (ARDS), sponsored by Qilu Cell Therapy. Started May 2025; status: active.
02
Drugs
umbilical cord mesenchymal stem cells (Shandong Province Qilu Stem Cells Engineering)
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on CTR20251847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251847.